Amylyx (NASDAQ: AMLX) Co-CEO Klee sells stock after option exercise

Q: Who is the insider in Amylyx Pharmaceuticals (AMLX) Form 4 filing?

The filing reports transactions by Justin B. Klee , who is a director and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc.

Q: What stock option exercises did Justin Klee report for AMLX in January 2026?

On January 15, 2026 , Klee exercised stock options for 197,153 shares of Amylyx common stock at an exercise price of $7.57 per share. On January 16, 2026 , he exercised options for another 2,847 shares at the same $7.57 exercise price.

Q: How many Amylyx (AMLX) shares did Justin Klee sell in this Form 4?

Klee sold 136,193 shares of Amylyx common stock on January 15, 2026 at a weighted average price of $13.5827 per share, and 1,995 shares on January 16, 2026 at a weighted average price of $13.8853 per share.

Q: How many Amylyx (AMLX) shares does Justin Klee own after these transactions?

Following the reported transactions, Justin Klee beneficially owned 3,379,398 shares of Amylyx Pharmaceuticals common stock, held with direct ownership .

Q: What is the status of the stock options mentioned in the AMLX Form 4?

The Form 4 notes that the reported stock option is fully vested and exercisable and is due to expire on February 19, 2026 , with an exercise price of $7.57 per share.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Co-Chief Executive Officer and director Justin B. Klee reported option exercises and related share sales. On January 15, 2026, he exercised stock options for 197,153 shares of common stock at an exercise price of $7.57 per share, then sold 136,193 shares at a weighted average price of $13.5827 per share. On January 16, 2026, he exercised options for an additional 2,847 shares at $7.57 and sold 1,995 shares at a weighted average price of $13.8853 per share. According to the footnotes, these sales were made to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Klee directly held 3,379,398 shares of Amylyx common stock.

Insider Trade Summary

Net Seller: 138,188 shares ($1,877,570)

Net Sell 6 txns

Insider Klee Justin B.

Role Co-Chief Executive Officer

Sold 138,188 shs ($1.88M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,847	$0.00	--
Exercise	Common Stock	2,847	$7.57	$22K
Sale	Common Stock	1,995	$13.8853	$28K
Exercise	Stock Option (Right to Buy)	197,153	$0.00	--
Exercise	Common Stock	197,153	$7.57	$1.49M
Sale	Common Stock	136,193	$13.5827	$1.85M

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 3,381,393 shares (Direct)

Footnotes (1)

Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. This option is fully vested and exercisable. The option is due to expire on February 19, 2026.

Form 4 Insider Transactions: What Each Field Means →

01/20/2026 - 09:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klee Justin B.

(Last)

(First)

(Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/15/2026		M		197,153	A	$7.57	3,514,739	D
Common Stock	01/15/2026		S⁽¹⁾		136,193	D	$13.5827⁽²⁾	3,378,546	D
Common Stock	01/16/2026		M		2,847	A	$7.57	3,381,393	D
Common Stock	01/16/2026		S⁽¹⁾		1,995	D	$13.8853⁽³⁾	3,379,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.57	01/15/2026		M			197,153	⁽⁴⁾	02/19/2026	Common Stock	197,153	$0.00	2,847	D
Stock Option (Right to Buy)	$7.57	01/16/2026		M			2,847	⁽⁴⁾	02/19/2026	Common Stock	2,847	$0.00	0.00	D

Explanation of Responses:

1. Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

4. This option is fully vested and exercisable. The option is due to expire on February 19, 2026.

	/s/ Joshua B. Cohen, as Attorney in Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in Amylyx Pharmaceuticals (AMLX) Form 4 filing?

The filing reports transactions by Justin B. Klee, who is a director and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc.

What stock option exercises did Justin Klee report for AMLX in January 2026?

On January 15, 2026, Klee exercised stock options for 197,153 shares of Amylyx common stock at an exercise price of $7.57 per share. On January 16, 2026, he exercised options for another 2,847 shares at the same $7.57 exercise price.

How many Amylyx (AMLX) shares did Justin Klee sell in this Form 4?

Klee sold 136,193 shares of Amylyx common stock on January 15, 2026 at a weighted average price of $13.5827 per share, and 1,995 shares on January 16, 2026 at a weighted average price of $13.8853 per share.

Why did Justin Klee sell Amylyx Pharmaceuticals (AMLX) shares in this filing?

According to the disclosure, the reported share sales reflect shares sold to cover option cost and tax obligations upon option exercise, and were made under a preset sales plan adopted by Klee on November 12, 2025.

How many Amylyx (AMLX) shares does Justin Klee own after these transactions?

Following the reported transactions, Justin Klee beneficially owned 3,379,398 shares of Amylyx Pharmaceuticals common stock, held with direct ownership.

What is the status of the stock options mentioned in the AMLX Form 4?

The Form 4 notes that the reported stock option is fully vested and exercisable and is due to expire on February 19, 2026, with an exercise price of $7.57 per share.